Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

Table 5 Other cerebrospinal fluid biomarkers at baseline

	Overall cohort	rpAD	Non-rpAD	p-value
NfL (pg/ml) median (IQR)	1878 (1203) n = 43	2393 (3023) n = 12	1699 (1229) n = 31	0.024*
t-PrP (ng/ml) median (IQR)	45.2 (28.53) n = 47	44.5 (20.05) n = 29	45.5 (34.2) n = 18	0.811
YKL-40 (pg/ml) median (IQR)	365.5 (88.8) n = 16	368 (195) n = 8	348 (95.5) n = 8	0.234
LCN2 (pg/ml) median (IQR)	800 (500) n = 19	880 (700) n = 7	780 (276) n = 12	0.853
α-Synuclein (pg/ml) median (IQR)	302 (349.8) n = 16	302 (426.3) n = 10	313.5 (277.3) n = 6	0.713

Abbreviations: rpAD, rapidly progressive Alzheimer’s disease; NfL, neurofilament light chain; glial fibrillary acidic protein, GFAP; t-PrP, total Prion protein; YKL-40, chitinase-3-like protein 1; LCN2, lipocalin2; IQR, interquartile range
^*p-values below significance threshold of 0.05. All biomarkers were measured before [29,30,31,32,33] and retrospectively re-evaluated

ISSN: 1758-9193